spacer
home > pmps > spring 2018 > digital double-win
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Digital Double-Win

Today’s pharmaceutical executives navigate extremely complex territory on a daily basis. The toughest quandary they face is existential in nature: how to survive and thrive in the digital economy. Digital developments present both risks – including those connected with business, security, and compliance – and tremendous upside performance transformation opportunities.

Industry headlines are forcing executives to think long and hard about their digital transformation strategies. Consider these sample, thought-provoking headlines:

• Why did CVS buy Aetna for $69 billion? (1)
• Mylan and Teva stocks rise on report about Amazon’s pharmacy aims (2)
• Hearing Amazon’s footsteps, the healthcare industry shudders (3)
• Big Pharma builds blockchain prototype to stop counterfeits (4)
• FDA pushes DSCSA serialisation enforcement deadline to 2018 (5)
• Pharma’s digital supply chain transformation (6)

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Evren Ozkaya PhD is the Founder and CEO of Supply Chain Wizard: a full-service global consulting firm specialising in serialisation and traceability as well as supply chain strategy and operational transformation programmes. Supply Chain Wizard offers products and services targeting serialisation and supply chain transformation initiatives, along with a team of consultants providing comprehensive support towards cost-effective compliance with serialisation mandates and post-go-live operational support. Email:
spacer
Dr Evren Ozkaya
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

Clinical Trial Supply Europe 2019

13-14 March 2019, Milan, Italy

Following on from our largest and most engaging meeting to date, Clinical Trial Supply Europe will be returning to Milan for its 20th year in 2019! The 19th annual edition welcomed pharmaceutical companies across Europe who got together to share knowledge and issues regarding clinical trial supplies, both with regards to operational and technological challenges. Over the two days, delegates discussed issues which affected their business in our dedicated operational and technological streams.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement